Metriopharm’s ‘iMPact’ project was awarded a €7.9 million grant from the COVID-19 work programme from Horizon Europe in November of 2021, to clinically validate MP1032, an early intervention treatment against mild-to-moderate COVID-19. In this project, MetrioPharm has joined forces with three consortium partners, ImmunoLogik, Catalyze, and PHOX Consulting e.U. Our Partner Catalyze spoke with Dr. Wolfgang Brysch, Chief Scientific Officer and Chief Medical Officer of Metriopharm, to hear more about their mission, the iMPact project. Here is the article:
Monthly Archives: January 2022
Ralf Haubert
Marketing Manager
blog@metriopharm.com
- Unlocking the Potential: Webinar “Host Directed Therapies, MP1032 and its Implications in Infectious Diseases”
- The Full Potential of MP1032: MetrioPharm Publishes Annual Report 2021
- Metriopharm’s early intervention treatment for mild-moderate COVID- 19
- “The Path to the Clinical Trial”
- SARS-CoV-2 and Mitochondrial Health
- 13.03.2024 MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
- 31.01.2024 MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
- 25.10.2023 MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
- 30.05.2023 MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy